Insider Selling: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CFO Sells 11,000 Shares of Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. The trade was a 17.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA opened at $8.07 on Friday. The firm has a market capitalization of $430.78 million, a price-to-earnings ratio of -4.10 and a beta of 2.00. Zevra Therapeutics, Inc. has a one year low of $4.20 and a one year high of $9.76. The business has a fifty day simple moving average of $8.22 and a 200 day simple moving average of $8.06. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC raised its position in Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Zevra Therapeutics in the 4th quarter worth approximately $94,000. Hunter Associates Investment Management LLC bought a new position in shares of Zevra Therapeutics during the 3rd quarter worth approximately $92,000. XTX Topco Ltd acquired a new stake in Zevra Therapeutics in the 3rd quarter valued at $94,000. Finally, Intech Investment Management LLC bought a new stake in Zevra Therapeutics in the third quarter valued at $95,000. 35.03% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ZVRA has been the topic of several recent analyst reports. Cantor Fitzgerald raised Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 29th. Canaccord Genuity Group dropped their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $21.57.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.